Vancouver, B.C. – Acuitas Therapeutics has entered into a new, long-term partnership with Science World, President & CEO Dr. Thomas Madden has announced. The integrated engagement between the two organizations concentrates on human health and enrichment education and is founded on a mutual alignment in areas such as delivering life sciences content and promoting sciences, technology, engineering, the arts and math (STEAM) education. It will focus on creating interest in STEAM-based careers, including participation by the Acuitas team in Girls in STEAM and other events, with the goal of inspiring the next generation of innovators.
“Everyone on the Acuitas team is committed to promoting and supporting interest in STEAM-based careers,” said Dr. Madden. He added: “We believe that our partnership with Science World – which is such a well-respected and well-known organization – is an exceptional opportunity for us to proactively contribute in this area. We are delighted to be partnering with Science World and look forward to working with them to showcase how challenging and rewarding a STEAM career can be.”
“The team at Acuitas is passionate about building a pipeline of talent in STEAM fields and through the work they do and have been able to positively impact millions of people all over the world,” said Tracy Redies, Science World President and CEO. “Seeing a BC-based company achieve what they have is truly inspiring. With their vision and goals so closely aligned with Science World’s, we’re very excited about the long-term relationship we are building with them and we look forward to working with their entire team.”
About Science World
Science World is a BC-based charitable organization that engages the people of British Columbia in STEAM literacy. Their mission is to ignite wonder and empower dreams through science and nature. Their vision is that within a generation, Canada will be a country of thriving, sustainable communities rooted in science, innovation and a deep connection to nature.
About Acuitas Therapeutics
Founded in February 2009, Vancouver-based Acuitas Therapeutics (www.acuitastx.com) is a private biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles. The company partners with pharmaceutical and biotechnology companies and academic institutes to advance nucleic acid therapeutics into clinical trials and to the marketplace. The team works with partners to develop new therapies to address unmet clinical needs based on its internationally recognized capabilities in delivery technology. Acuitas Therapeutics has agreements in place with several partners to use its proprietary lipid nanotechnology in the development of COVID-19 vaccines. These include Pfizer/BioNTech for COMIRNATY®, which has received full approval in the U.S. and Canada and is authorized for Emergency Use in Europe, the UK and many other countries.
